<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25856">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770157</url>
  </required_header>
  <id_info>
    <org_study_id>DA3002_SGA_III</org_study_id>
    <nct_id>NCT02770157</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DA-3002 in Short Children Borns SGA.</brief_title>
  <acronym>SGA</acronym>
  <official_title>Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Short Children Born Small for Gestational Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin® in short
      children born small for gestational age.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A comparison of annualized height velocity between the DA-3002 treated group and the Genotropin® treated group after 52 weeks.</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Infant, Small for Gestational Age</condition>
  <arm_group>
    <arm_group_label>DA-3002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotropin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.44 IU (0.48mg)/kg/week of Genotropin is injected for 52 weeks by changing injecting areas(six or seven times per week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-treatment control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After no treatment for 26 weeks, 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-3002</intervention_name>
    <arm_group_label>DA-3002</arm_group_label>
    <arm_group_label>Non-treatment control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genotropin®</intervention_name>
    <arm_group_label>Genotropin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronological Age ≥ 4

          -  Before the adolescence, Tuner stage I (breast)

          -  Height &lt;3rd percentile for age

          -  Normal thyroid function

        Exclusion Criteria:

          -  Growth hormone was administered for 12 months or longer in the past

          -  Treated with estrogen or adrenal androgens for 12 months or longer in the past

          -  Malignancy, CNS Trauma, Psychiatric Disorder

          -  endocrine and/or metabolic disorders

          -  growth failure caused by other disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong kyu Jin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Samsung Medical center.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung Kyu Suh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheol Woo Ko, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kee Hyoung Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Han Wook Yoo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Choong Ho Shin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Soon Hwang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aju University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ho Seong Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Children's Hospital Yonsei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Young Jeong, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang Jong Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heon Suk Han, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong kyu Jin, M.D., Ph.D.</last_name>
    <phone>82-2-1599-3114</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Kyu Jin, Ph D.</last_name>
      <phone>82-2-1599-3114</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 10, 2016</lastchanged_date>
  <firstreceived_date>May 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
